Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Illumina, Inc.NASDAQ: ILMN
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue growth accelerates
Q2 FY2026 revenue of $1.16B rose 9.6% year over year, ahead of the +4.9% change in trailing-twelve-month revenue. Sequentially, it rose 6.2% from the prior quarter. Over 3 fiscal years it compounded at -1.8% a year.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 14 analysts of $4.63B (+6.7%) for the fiscal year ending Dec 2026, a step up from the -0.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.16B+6.2% QoQ
- Last fiscal yearDec 2025
- $4.34B-0.8% YoY
- LTMJun 2026
- $4.49B+4.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.6% | +6.5% | -3.2 pp |
| 1 year | -0.8% | +6.7% | +7.5 pp |
| 3-year CAGR | -1.8% | +7.1% | +8.9 pp |
| 5-year CAGR | +7.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 4.34B USD
- Year-over-year change
- -0.8%
- 4-year CAGR
- -1.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 4.34B | -0.8% |
| FY2024 | 2024-12-29 | 4.37B | -2.9% |
| FY2023 | 2023-12-31 | 4.5B | -1.7% |
| FY2022 | 2023-01-01 | 4.58B | +1.3% |
| FY2021 | 2022-01-02 | 4.53B | — |
Revenue vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 revenue of $4.49B is the highest of the 11 companies compared; the peer median is $536.5M.
- Its year-over-year change of +4.9% is the 8th highest of 11, against a peer median of +16.0%.
- Over three fiscal years its annual growth of -1.8% compares with a peer median of +15.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $4.49B | +4.9% | -1.8% | |
| LTM Jun 2026 | $2.71B | +37.8% | +41.1% | |
| LTM Sep 2026 | $1.28B | +41.7% | +29.8% | |
| LTM Mar 2026 | $829M | -0.3% | +6.7% | |
| LTM Jun 2026 | $766.3M | +11.2% | +12.6% | |
| LTM Sep 2026 | $618.58M | -3.6% | +7.6% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $454.43M | +25.4% | +22.1% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $397.41M | +90.1% | — |
| LTM Mar 2026 | $160.03M | +5.0% | +7.6% | |
| LTM Mar 2026 | $81.18M | +20.9% | +17.6% | |
| LTM Mar 2026 | $64.52M | -24.7% | — | |
| Peer median (excluding ILMN) | $536.5M | +16.0% | +15.1% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.53B | 4.58B | 4.5B | 4.37B | 4.34B |
| Cost of Revenue | 1.37B | 1.61B | 1.76B | 1.51B | 1.45B |
| Gross Profit | 3.15B | 2.97B | 2.74B | 2.86B | 2.89B |
| Gross Margin | 69.7% | 64.8% | 60.9% | 65.4% | 66.7% |
| Research & Development | 1.19B | 1.32B | 1.35B | 1.17B | 951M |
| Selling, General & Admin | 2.09B | 1.3B | 1.61B | 1.09B | 1.08B |
| Operating Expenses | 3.28B | 7.15B | 3.81B | 3.69B | 2.03B |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| EBITDA | 1.2B | (3.92B) | (608M) | (725M) | 1.46B |
| EBITDA Margin | 26.4% | -85.4% | -13.5% | -16.6% | 33.6% |
| Operating Income | (123M) | (4.18B) | (1.07B) | (833M) | 864M |
| Operating Margin | -2.7% | -91.2% | -23.7% | -19.1% | 19.9% |
| Interest Income | 0 | 11M | 58M | 46M | 40M |
| Interest Expense | 61M | 26M | 77M | 100M | 101M |
| Other Income / Expenses | 1.01B | (157M) | (48M) | (346M) | 222M |
| Income Before Tax | 884M | (4.34B) | (1.12B) | (1.18B) | 1.09B |
| Pre-Tax Margin | 19.5% | -94.6% | -24.8% | -27.0% | 25.0% |
| Income Tax Expense | 122M | 68M | 44M | 44M | 236M |
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Net Margin | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| EPS (Basic) | 5.08 | (28.05) | (7.35) | (7.69) | 5.48 |
| EPS (Diluted) | 5.05 | (28.05) | (7.35) | (7.69) | 5.45 |
| Weighted Avg Shares | 150M | 157M | 158M | 159M | 155M |
| Weighted Avg Shares (Diluted) | 151M | 157M | 158M | 159M | 156M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.